Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
25,125
archived clinical trials in
Diabetes

Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Green Bay, WI
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Green Bay, WI
Click here to add this to my saved trials
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Kenosha, WI
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Kenosha, WI
Click here to add this to my saved trials
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Madison, WI
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Madison, WI
Click here to add this to my saved trials
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated:  12/31/1969
Merck Sharp & Dohme (Argentina) Inc.
mi
from
Buenos Aires,
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated: 12/31/1969
Merck Sharp & Dohme (Argentina) Inc.
mi
from
Buenos Aires,
Click here to add this to my saved trials
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Methuen, MA
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Methuen, MA
Click here to add this to my saved trials
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Hazelwood, MO
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Hazelwood, MO
Click here to add this to my saved trials
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Hopewell Junction, NY
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Hopewell Junction, NY
Click here to add this to my saved trials
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
New Windsor, NY
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
New Windsor, NY
Click here to add this to my saved trials
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Moncks Corner, SC
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Moncks Corner, SC
Click here to add this to my saved trials
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Macon, GA
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Macon, GA
Click here to add this to my saved trials
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Desoto, TX
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Desoto, TX
Click here to add this to my saved trials
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Raleigh, NC
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Raleigh, NC
Click here to add this to my saved trials
Efficacy and Safety of Nasal Glucagon for Treatment of Hypoglycemia in Adults
Efficacy and Safety of Nasal Glucagon for Treatment of Insulin Induced Hypoglycemia in Adults With Diabetes
Status: Enrolling
Updated:  12/31/1969
Barbara Davis Center for Diabetes
mi
from
Aurora, CO
Efficacy and Safety of Nasal Glucagon for Treatment of Hypoglycemia in Adults
Efficacy and Safety of Nasal Glucagon for Treatment of Insulin Induced Hypoglycemia in Adults With Diabetes
Status: Enrolling
Updated: 12/31/1969
Barbara Davis Center for Diabetes
mi
from
Aurora, CO
Click here to add this to my saved trials
Efficacy and Safety of Nasal Glucagon for Treatment of Hypoglycemia in Adults
Efficacy and Safety of Nasal Glucagon for Treatment of Insulin Induced Hypoglycemia in Adults With Diabetes
Status: Enrolling
Updated:  12/31/1969
Oregon Health and Science University
mi
from
Portland, OR
Efficacy and Safety of Nasal Glucagon for Treatment of Hypoglycemia in Adults
Efficacy and Safety of Nasal Glucagon for Treatment of Insulin Induced Hypoglycemia in Adults With Diabetes
Status: Enrolling
Updated: 12/31/1969
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
Efficacy and Safety of Nasal Glucagon for Treatment of Hypoglycemia in Adults
Efficacy and Safety of Nasal Glucagon for Treatment of Insulin Induced Hypoglycemia in Adults With Diabetes
Status: Enrolling
Updated:  12/31/1969
Riley Hospital for Children at Indiana University Health
mi
from
Indianapolis, IN
Efficacy and Safety of Nasal Glucagon for Treatment of Hypoglycemia in Adults
Efficacy and Safety of Nasal Glucagon for Treatment of Insulin Induced Hypoglycemia in Adults With Diabetes
Status: Enrolling
Updated: 12/31/1969
Riley Hospital for Children at Indiana University Health
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Efficacy and Safety of Nasal Glucagon for Treatment of Hypoglycemia in Adults
Efficacy and Safety of Nasal Glucagon for Treatment of Insulin Induced Hypoglycemia in Adults With Diabetes
Status: Enrolling
Updated:  12/31/1969
University of Florida
mi
from
Gainesville, FL
Efficacy and Safety of Nasal Glucagon for Treatment of Hypoglycemia in Adults
Efficacy and Safety of Nasal Glucagon for Treatment of Insulin Induced Hypoglycemia in Adults With Diabetes
Status: Enrolling
Updated: 12/31/1969
University of Florida
mi
from
Gainesville, FL
Click here to add this to my saved trials
Efficacy and Safety of Nasal Glucagon for Treatment of Hypoglycemia in Adults
Efficacy and Safety of Nasal Glucagon for Treatment of Insulin Induced Hypoglycemia in Adults With Diabetes
Status: Enrolling
Updated:  12/31/1969
Univ of Minnesota
mi
from
Minneapolis, MN
Efficacy and Safety of Nasal Glucagon for Treatment of Hypoglycemia in Adults
Efficacy and Safety of Nasal Glucagon for Treatment of Insulin Induced Hypoglycemia in Adults With Diabetes
Status: Enrolling
Updated: 12/31/1969
Univ of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Efficacy and Safety of Nasal Glucagon for Treatment of Hypoglycemia in Adults
Efficacy and Safety of Nasal Glucagon for Treatment of Insulin Induced Hypoglycemia in Adults With Diabetes
Status: Enrolling
Updated:  12/31/1969
Univ of Pennsylvania
mi
from
Philadelphia, PA
Efficacy and Safety of Nasal Glucagon for Treatment of Hypoglycemia in Adults
Efficacy and Safety of Nasal Glucagon for Treatment of Insulin Induced Hypoglycemia in Adults With Diabetes
Status: Enrolling
Updated: 12/31/1969
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Efficacy and Safety of Nasal Glucagon for Treatment of Hypoglycemia in Adults
Efficacy and Safety of Nasal Glucagon for Treatment of Insulin Induced Hypoglycemia in Adults With Diabetes
Status: Enrolling
Updated:  12/31/1969
UPA Buffalo
mi
from
Buffalo, NY
Efficacy and Safety of Nasal Glucagon for Treatment of Hypoglycemia in Adults
Efficacy and Safety of Nasal Glucagon for Treatment of Insulin Induced Hypoglycemia in Adults With Diabetes
Status: Enrolling
Updated: 12/31/1969
UPA Buffalo
mi
from
Buffalo, NY
Click here to add this to my saved trials
Efficacy and Safety of Nasal Glucagon for Treatment of Hypoglycemia in Adults
Efficacy and Safety of Nasal Glucagon for Treatment of Insulin Induced Hypoglycemia in Adults With Diabetes
Status: Enrolling
Updated:  12/31/1969
Yale University
mi
from
New Haven, CT
Efficacy and Safety of Nasal Glucagon for Treatment of Hypoglycemia in Adults
Efficacy and Safety of Nasal Glucagon for Treatment of Insulin Induced Hypoglycemia in Adults With Diabetes
Status: Enrolling
Updated: 12/31/1969
Yale University
mi
from
New Haven, CT
Click here to add this to my saved trials
Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes
Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes
Status: Enrolling
Updated:  12/31/1969
Barbara Davis Center for Diabetes
mi
from
Aurora, CO
Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes
Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes
Status: Enrolling
Updated: 12/31/1969
Barbara Davis Center for Diabetes
mi
from
Aurora, CO
Click here to add this to my saved trials
Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes
Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes
Status: Enrolling
Updated:  12/31/1969
Nemours Children's Clinic
mi
from
Jacksonville, FL
Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes
Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes
Status: Enrolling
Updated: 12/31/1969
Nemours Children's Clinic
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes
Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes
Status: Enrolling
Updated:  12/31/1969
Riley Hospital for Children at Indiana University Health
mi
from
Indianapolis, IN
Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes
Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes
Status: Enrolling
Updated: 12/31/1969
Riley Hospital for Children at Indiana University Health
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes
Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes
Status: Enrolling
Updated:  12/31/1969
University of Florida
mi
from
Gainesville, FL
Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes
Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes
Status: Enrolling
Updated: 12/31/1969
University of Florida
mi
from
Gainesville, FL
Click here to add this to my saved trials
Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes
Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes
Status: Enrolling
Updated:  12/31/1969
Univ of Minnesota
mi
from
Minneapolis, MN
Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes
Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes
Status: Enrolling
Updated: 12/31/1969
Univ of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes
Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes
Status: Enrolling
Updated:  12/31/1969
UPA Buffalo
mi
from
Buffalo, NY
Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes
Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes
Status: Enrolling
Updated: 12/31/1969
UPA Buffalo
mi
from
Buffalo, NY
Click here to add this to my saved trials
Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes
Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes
Status: Enrolling
Updated:  12/31/1969
Yale University
mi
from
New Haven, CT
Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes
Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes
Status: Enrolling
Updated: 12/31/1969
Yale University
mi
from
New Haven, CT
Click here to add this to my saved trials
Examination of the Pancreas in New-onset Diabetes
Examination of the Pancreas in New-onset Diabetes (EXPAND Study)
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic Rochester
mi
from
Rochester, MN
Examination of the Pancreas in New-onset Diabetes
Examination of the Pancreas in New-onset Diabetes (EXPAND Study)
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic Rochester
mi
from
Rochester, MN
Click here to add this to my saved trials
The Use of Glutamic Acid Decarboxylase (GAD) and Gamma-Amino Butyric Acid (GABA) in the Treatment of Type I Diabetes
The Use of Glutamic Acid Decarboxylase (GAD)and Gamma-Amino Butyric Acid(GABA)in the Treatment of Type I Diabetes.
Status: Enrolling
Updated:  12/31/1969
Children's of Alabama
mi
from
Birmingham, AL
The Use of Glutamic Acid Decarboxylase (GAD) and Gamma-Amino Butyric Acid (GABA) in the Treatment of Type I Diabetes
The Use of Glutamic Acid Decarboxylase (GAD)and Gamma-Amino Butyric Acid(GABA)in the Treatment of Type I Diabetes.
Status: Enrolling
Updated: 12/31/1969
Children's of Alabama
mi
from
Birmingham, AL
Click here to add this to my saved trials
Post Approval Study of the TS Feature With the 530G Pump System Supplemented With Commercial Patient Data
Post Approval Study of the TS (Threshold Suspend) Feature With a Sensor-Augmented Pump System Supplemented With Commercial Patient Data
Status: Enrolling
Updated:  12/31/1969
Medical Investigations, Inc.
mi
from
Little Rock, AR
Post Approval Study of the TS Feature With the 530G Pump System Supplemented With Commercial Patient Data
Post Approval Study of the TS (Threshold Suspend) Feature With a Sensor-Augmented Pump System Supplemented With Commercial Patient Data
Status: Enrolling
Updated: 12/31/1969
Medical Investigations, Inc.
mi
from
Little Rock, AR
Click here to add this to my saved trials
Post Approval Study of the TS Feature With the 530G Pump System Supplemented With Commercial Patient Data
Post Approval Study of the TS (Threshold Suspend) Feature With a Sensor-Augmented Pump System Supplemented With Commercial Patient Data
Status: Enrolling
Updated:  12/31/1969
AMCR Institute, Inc
mi
from
Escondido, CA
Post Approval Study of the TS Feature With the 530G Pump System Supplemented With Commercial Patient Data
Post Approval Study of the TS (Threshold Suspend) Feature With a Sensor-Augmented Pump System Supplemented With Commercial Patient Data
Status: Enrolling
Updated: 12/31/1969
AMCR Institute, Inc
mi
from
Escondido, CA
Click here to add this to my saved trials
Post Approval Study of the TS Feature With the 530G Pump System Supplemented With Commercial Patient Data
Post Approval Study of the TS (Threshold Suspend) Feature With a Sensor-Augmented Pump System Supplemented With Commercial Patient Data
Status: Enrolling
Updated:  12/31/1969
Valley Research
mi
from
Fresno, CA
Post Approval Study of the TS Feature With the 530G Pump System Supplemented With Commercial Patient Data
Post Approval Study of the TS (Threshold Suspend) Feature With a Sensor-Augmented Pump System Supplemented With Commercial Patient Data
Status: Enrolling
Updated: 12/31/1969
Valley Research
mi
from
Fresno, CA
Click here to add this to my saved trials
Post Approval Study of the TS Feature With the 530G Pump System Supplemented With Commercial Patient Data
Post Approval Study of the TS (Threshold Suspend) Feature With a Sensor-Augmented Pump System Supplemented With Commercial Patient Data
Status: Enrolling
Updated:  12/31/1969
Center of Excellence in Diabetes & Endocrinology
mi
from
Sacramento, CA
Post Approval Study of the TS Feature With the 530G Pump System Supplemented With Commercial Patient Data
Post Approval Study of the TS (Threshold Suspend) Feature With a Sensor-Augmented Pump System Supplemented With Commercial Patient Data
Status: Enrolling
Updated: 12/31/1969
Center of Excellence in Diabetes & Endocrinology
mi
from
Sacramento, CA
Click here to add this to my saved trials
Post Approval Study of the TS Feature With the 530G Pump System Supplemented With Commercial Patient Data
Post Approval Study of the TS (Threshold Suspend) Feature With a Sensor-Augmented Pump System Supplemented With Commercial Patient Data
Status: Enrolling
Updated:  12/31/1969
So Cal Diabetes
mi
from
Torrance, CA
Post Approval Study of the TS Feature With the 530G Pump System Supplemented With Commercial Patient Data
Post Approval Study of the TS (Threshold Suspend) Feature With a Sensor-Augmented Pump System Supplemented With Commercial Patient Data
Status: Enrolling
Updated: 12/31/1969
So Cal Diabetes
mi
from
Torrance, CA
Click here to add this to my saved trials
Post Approval Study of the TS Feature With the 530G Pump System Supplemented With Commercial Patient Data
Post Approval Study of the TS (Threshold Suspend) Feature With a Sensor-Augmented Pump System Supplemented With Commercial Patient Data
Status: Enrolling
Updated:  12/31/1969
Endocrine Associates of Florida, P.A.
mi
from
Lake Mary, FL
Post Approval Study of the TS Feature With the 530G Pump System Supplemented With Commercial Patient Data
Post Approval Study of the TS (Threshold Suspend) Feature With a Sensor-Augmented Pump System Supplemented With Commercial Patient Data
Status: Enrolling
Updated: 12/31/1969
Endocrine Associates of Florida, P.A.
mi
from
Lake Mary, FL
Click here to add this to my saved trials
Post Approval Study of the TS Feature With the 530G Pump System Supplemented With Commercial Patient Data
Post Approval Study of the TS (Threshold Suspend) Feature With a Sensor-Augmented Pump System Supplemented With Commercial Patient Data
Status: Enrolling
Updated:  12/31/1969
TLC Diabetes Healthcare Consultants & Education Inc.
mi
from
Naples, FL
Post Approval Study of the TS Feature With the 530G Pump System Supplemented With Commercial Patient Data
Post Approval Study of the TS (Threshold Suspend) Feature With a Sensor-Augmented Pump System Supplemented With Commercial Patient Data
Status: Enrolling
Updated: 12/31/1969
TLC Diabetes Healthcare Consultants & Education Inc.
mi
from
Naples, FL
Click here to add this to my saved trials
Post Approval Study of the TS Feature With the 530G Pump System Supplemented With Commercial Patient Data
Post Approval Study of the TS (Threshold Suspend) Feature With a Sensor-Augmented Pump System Supplemented With Commercial Patient Data
Status: Enrolling
Updated:  12/31/1969
Pediatric Endocrine Associates
mi
from
Tampa, FL
Post Approval Study of the TS Feature With the 530G Pump System Supplemented With Commercial Patient Data
Post Approval Study of the TS (Threshold Suspend) Feature With a Sensor-Augmented Pump System Supplemented With Commercial Patient Data
Status: Enrolling
Updated: 12/31/1969
Pediatric Endocrine Associates
mi
from
Tampa, FL
Click here to add this to my saved trials
Post Approval Study of the TS Feature With the 530G Pump System Supplemented With Commercial Patient Data
Post Approval Study of the TS (Threshold Suspend) Feature With a Sensor-Augmented Pump System Supplemented With Commercial Patient Data
Status: Enrolling
Updated:  12/31/1969
Atlanta Diabetes Associates
mi
from
Atlanta, GA
Post Approval Study of the TS Feature With the 530G Pump System Supplemented With Commercial Patient Data
Post Approval Study of the TS (Threshold Suspend) Feature With a Sensor-Augmented Pump System Supplemented With Commercial Patient Data
Status: Enrolling
Updated: 12/31/1969
Atlanta Diabetes Associates
mi
from
Atlanta, GA
Click here to add this to my saved trials
Post Approval Study of the TS Feature With the 530G Pump System Supplemented With Commercial Patient Data
Post Approval Study of the TS (Threshold Suspend) Feature With a Sensor-Augmented Pump System Supplemented With Commercial Patient Data
Status: Enrolling
Updated:  12/31/1969
East Alabama Endocrinology PC
mi
from
Columbus, GA
Post Approval Study of the TS Feature With the 530G Pump System Supplemented With Commercial Patient Data
Post Approval Study of the TS (Threshold Suspend) Feature With a Sensor-Augmented Pump System Supplemented With Commercial Patient Data
Status: Enrolling
Updated: 12/31/1969
East Alabama Endocrinology PC
mi
from
Columbus, GA
Click here to add this to my saved trials
Post Approval Study of the TS Feature With the 530G Pump System Supplemented With Commercial Patient Data
Post Approval Study of the TS (Threshold Suspend) Feature With a Sensor-Augmented Pump System Supplemented With Commercial Patient Data
Status: Enrolling
Updated:  12/31/1969
Endocrine Research Solutions, Inc.
mi
from
Roswell, GA
Post Approval Study of the TS Feature With the 530G Pump System Supplemented With Commercial Patient Data
Post Approval Study of the TS (Threshold Suspend) Feature With a Sensor-Augmented Pump System Supplemented With Commercial Patient Data
Status: Enrolling
Updated: 12/31/1969
Endocrine Research Solutions, Inc.
mi
from
Roswell, GA
Click here to add this to my saved trials
Post Approval Study of the TS Feature With the 530G Pump System Supplemented With Commercial Patient Data
Post Approval Study of the TS (Threshold Suspend) Feature With a Sensor-Augmented Pump System Supplemented With Commercial Patient Data
Status: Enrolling
Updated:  12/31/1969
University of Chicago
mi
from
Chicago, IL
Post Approval Study of the TS Feature With the 530G Pump System Supplemented With Commercial Patient Data
Post Approval Study of the TS (Threshold Suspend) Feature With a Sensor-Augmented Pump System Supplemented With Commercial Patient Data
Status: Enrolling
Updated: 12/31/1969
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Post Approval Study of the TS Feature With the 530G Pump System Supplemented With Commercial Patient Data
Post Approval Study of the TS (Threshold Suspend) Feature With a Sensor-Augmented Pump System Supplemented With Commercial Patient Data
Status: Enrolling
Updated:  12/31/1969
Isaiah Pittman IV, MD
mi
from
Terre Haute, IN
Post Approval Study of the TS Feature With the 530G Pump System Supplemented With Commercial Patient Data
Post Approval Study of the TS (Threshold Suspend) Feature With a Sensor-Augmented Pump System Supplemented With Commercial Patient Data
Status: Enrolling
Updated: 12/31/1969
Isaiah Pittman IV, MD
mi
from
Terre Haute, IN
Click here to add this to my saved trials
Post Approval Study of the TS Feature With the 530G Pump System Supplemented With Commercial Patient Data
Post Approval Study of the TS (Threshold Suspend) Feature With a Sensor-Augmented Pump System Supplemented With Commercial Patient Data
Status: Enrolling
Updated:  12/31/1969
Good Samaritan Hospital Physician Services
mi
from
Vincennes, IN
Post Approval Study of the TS Feature With the 530G Pump System Supplemented With Commercial Patient Data
Post Approval Study of the TS (Threshold Suspend) Feature With a Sensor-Augmented Pump System Supplemented With Commercial Patient Data
Status: Enrolling
Updated: 12/31/1969
Good Samaritan Hospital Physician Services
mi
from
Vincennes, IN
Click here to add this to my saved trials
Post Approval Study of the TS Feature With the 530G Pump System Supplemented With Commercial Patient Data
Post Approval Study of the TS (Threshold Suspend) Feature With a Sensor-Augmented Pump System Supplemented With Commercial Patient Data
Status: Enrolling
Updated:  12/31/1969
Iowa Diabetes and Endocrinology Center
mi
from
Des Moines, IA
Post Approval Study of the TS Feature With the 530G Pump System Supplemented With Commercial Patient Data
Post Approval Study of the TS (Threshold Suspend) Feature With a Sensor-Augmented Pump System Supplemented With Commercial Patient Data
Status: Enrolling
Updated: 12/31/1969
Iowa Diabetes and Endocrinology Center
mi
from
Des Moines, IA
Click here to add this to my saved trials
Post Approval Study of the TS Feature With the 530G Pump System Supplemented With Commercial Patient Data
Post Approval Study of the TS (Threshold Suspend) Feature With a Sensor-Augmented Pump System Supplemented With Commercial Patient Data
Status: Enrolling
Updated:  12/31/1969
Imperial Health
mi
from
Lake Charles, LA
Post Approval Study of the TS Feature With the 530G Pump System Supplemented With Commercial Patient Data
Post Approval Study of the TS (Threshold Suspend) Feature With a Sensor-Augmented Pump System Supplemented With Commercial Patient Data
Status: Enrolling
Updated: 12/31/1969
Imperial Health
mi
from
Lake Charles, LA
Click here to add this to my saved trials
Post Approval Study of the TS Feature With the 530G Pump System Supplemented With Commercial Patient Data
Post Approval Study of the TS (Threshold Suspend) Feature With a Sensor-Augmented Pump System Supplemented With Commercial Patient Data
Status: Enrolling
Updated:  12/31/1969
Eastern Shore Diabetes and Endocrinology Center
mi
from
Salisbury, MD
Post Approval Study of the TS Feature With the 530G Pump System Supplemented With Commercial Patient Data
Post Approval Study of the TS (Threshold Suspend) Feature With a Sensor-Augmented Pump System Supplemented With Commercial Patient Data
Status: Enrolling
Updated: 12/31/1969
Eastern Shore Diabetes and Endocrinology Center
mi
from
Salisbury, MD
Click here to add this to my saved trials
Post Approval Study of the TS Feature With the 530G Pump System Supplemented With Commercial Patient Data
Post Approval Study of the TS (Threshold Suspend) Feature With a Sensor-Augmented Pump System Supplemented With Commercial Patient Data
Status: Enrolling
Updated:  12/31/1969
Grunberger Diabetes Institute
mi
from
Bloomfield Hills, MI
Post Approval Study of the TS Feature With the 530G Pump System Supplemented With Commercial Patient Data
Post Approval Study of the TS (Threshold Suspend) Feature With a Sensor-Augmented Pump System Supplemented With Commercial Patient Data
Status: Enrolling
Updated: 12/31/1969
Grunberger Diabetes Institute
mi
from
Bloomfield Hills, MI
Click here to add this to my saved trials
Post Approval Study of the TS Feature With the 530G Pump System Supplemented With Commercial Patient Data
Post Approval Study of the TS (Threshold Suspend) Feature With a Sensor-Augmented Pump System Supplemented With Commercial Patient Data
Status: Enrolling
Updated:  12/31/1969
Spectrum Health System
mi
from
Grand Rapids, MI
Post Approval Study of the TS Feature With the 530G Pump System Supplemented With Commercial Patient Data
Post Approval Study of the TS (Threshold Suspend) Feature With a Sensor-Augmented Pump System Supplemented With Commercial Patient Data
Status: Enrolling
Updated: 12/31/1969
Spectrum Health System
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
Post Approval Study of the TS Feature With the 530G Pump System Supplemented With Commercial Patient Data
Post Approval Study of the TS (Threshold Suspend) Feature With a Sensor-Augmented Pump System Supplemented With Commercial Patient Data
Status: Enrolling
Updated:  12/31/1969
International Diabetes Center
mi
from
Minneapolis, MN
Post Approval Study of the TS Feature With the 530G Pump System Supplemented With Commercial Patient Data
Post Approval Study of the TS (Threshold Suspend) Feature With a Sensor-Augmented Pump System Supplemented With Commercial Patient Data
Status: Enrolling
Updated: 12/31/1969
International Diabetes Center
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Post Approval Study of the TS Feature With the 530G Pump System Supplemented With Commercial Patient Data
Post Approval Study of the TS (Threshold Suspend) Feature With a Sensor-Augmented Pump System Supplemented With Commercial Patient Data
Status: Enrolling
Updated:  12/31/1969
The Mayo Clinic
mi
from
Rochester, MN
Post Approval Study of the TS Feature With the 530G Pump System Supplemented With Commercial Patient Data
Post Approval Study of the TS (Threshold Suspend) Feature With a Sensor-Augmented Pump System Supplemented With Commercial Patient Data
Status: Enrolling
Updated: 12/31/1969
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials